Google
NUVB 株価分析 — Nuvation Bio Inc (Healthcare >> Biotechnology)
NUVB に関するよくある質問
NUVBのPER（株価収益率）は？
Nuvation Bio Inc（NUVB）は現在PER 397.43倍で取引されています。
NUVBのROE（自己資本利益率）は？
Nuvation Bio IncのROEは-45.69%です。
NUVBの配当利回りは？
Nuvation Bio Incの配当利回りは0.00%です。
NUVBの品質スコア（Quality Score）は？
当社のAIはNUVBの総合財務品質を100点中54点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
NUVBは今が買い時ですか？
当社AIのタイミングスコアは100点中87点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
NUVBはどのセクターに属しますか？
Nuvation Bio IncはHealthcare >> Biotechnologyセクターに分類されます（NYSE市場）
NUVB AI Analysis Summary
Our AI summary for NUVB: Nuvation Bio Inc (NYSE), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 397.43, ROE of -45.69%, a dividend yield of 0.00%. Its financial Quality Score stands at 54/100 — mid-range fundamentals relative to the market. The AI Timing Score is 87/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 6.44
Price
0.28
(4.55%)
Day Change
|
|
|---|
NUVB, ファンダメンタルスコアはnot quite good ( ファンダメンタル = 54) but テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
P/Eが高い。割高銘柄。
ROEが低い
ROAが低い
平均ROEが低い
NPMが低い
NPMの伸びが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not quite good , and ability to make profit is not quite good , ...
| Deepscope 分析 |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 97 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 6.44 |
| PBV / Sector |
6.71 / 44,022.72
|
| Earning Per Share | -0.44 |
| PE / Sector |
397.43 / 19.17
|
| PEG or PE/Growth / Sector |
2.90 / 1.24
|
| Average 1M Daily Value |
36.65 M
GREAT
|
| Average 1W Daily Value |
30.98 M
GREAT
|
| Timing Factors |
|
57% |
| Financial Health |
|
50% |
| ポイントになる統計 |
|
52% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-08-05 08:00:37 |
| Symbol | NUVB |
| Name | NUVATION BIO INC |
| Sector | Healthcare >> Biotechnology |
| Market | NYSE |
| Listed Shares | 347.20 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 2,144.92 / 9,586.08 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 1500 Broadway, New York, NY, United States, 10036
Phone: 332 208 6102
Website: https://www.nuvationbio.com
Employees: 307
Sector: Healthcare >> Biotechnology
Description: Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo. The company was founded in 2018 and is headquartered in New York, New York.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
